Safety Reading Notes

Read safety context beside the research guide.

The CBG and skin/dermatology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 39596290

PubMed For Dummies Article

CBG and skin/dermatology Evidence Review: the long-form source walk-through

Quick read
  • CBG and skin/dermatology currently has 14 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 39596290
  • The evidence classes most visible in the row language are mechanistic or pharmacological (9), insufficient (3), preclinical (1), and preliminary human (1). PMID 36916438
  • The study-design language most visible in the row language is Cellular or in vitro study (7), Animal study (3), and Human clinical study (1). PMID 40725084
  • The repeated topics are Skin and inflammatory dermatology (14), which tells the reader where to start opening PubMed and DOI links. PMID 36768709

Start with the research question

CBG and skin/dermatology is built from 14 source-backed evidence row(s) and 14 research source(s). The current evidence classes read as mechanistic or pharmacological (9), insufficient (3), preclinical (1), and preliminary human (1), and the study-design language most often reads as Cellular or in vitro study (7), Animal study (3), and Human clinical study (1). PMID 39596290

The row-level question is not simply whether CBG and skin/dermatology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Skin and inflammatory dermatology (14). PMID 36768709

Human evidence 1 row

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 35056807

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39851511

Mechanistic evidence 9 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 40124934

Limits and uncertainty 3 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37949940

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 39647320

Where this page has the most source density

The largest bucket surfaced for this page is Skin and inflammatory dermatology: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Skin and inflammatory dermatology: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 39596290

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 36768709

Bucket chapters: what the literature is circling

Skin and inflammatory dermatology: mechanistic or pharmacological

9 research sources 9 rows (606-619) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: mechanistic or pharmacological. It currently draws from 9 research source(s), so the exact study type matters. PMID 39596290

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39596290

  • Evidence row 606

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, derm... PMID 39596290

  • Evidence row 619

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 27094344

Skin and inflammatory dermatology: insufficient

3 research sources 3 rows (609, 615, 618) Evidence class: insufficient

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: insufficient. It currently draws from 3 research source(s), so the exact study type matters. PMID 36768709

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 36768709

  • Evidence row 609

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36768709

  • Evidence row 615

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 38889235

Skin and inflammatory dermatology: preclinical

1 research source 607 Evidence class: preclinical

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: preclinical. It currently draws from 1 research source(s), so the exact study type matters. PMID 36916438

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 36916438

  • Evidence row 607

    CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36916438

Skin and inflammatory dermatology: preliminary human

1 research source 612 Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: preliminary human. It currently draws from 1 research source(s), so the exact study type matters. PMID 40124934

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 40124934

  • Evidence row 612

    CBG studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 40124934

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (1 row(s)), mechanistic evidence (9 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 39596290

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 36768709

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 38889235
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 37652708
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 39357769

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 39596290

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 36768709

Source-reading checklist for CBG and skin/dermatology

  1. Open the linked PubMed or DOI record. PMID 41645347
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 27094344
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 39596290
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 36916438
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 40725084

Source Notes

CBG and skin/dermatology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 606

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39596290

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.
  2. Evidence row 607

    CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36916438

    Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
  3. Evidence row 608

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 40725084

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea.
  4. Evidence row 609

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36768709

    Evidence class: insufficient. Source: Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota.
  5. Evidence row 610

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 35056807

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.
  6. Evidence row 611

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39851511

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway.
  7. Evidence row 612

    CBG studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 40124934

    Evidence class: preliminary human. Source: Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol.
  8. Evidence row 613

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 37949940

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives.
  9. Evidence row 614

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39647320

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests.
  10. Evidence row 615

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 38889235

    Evidence class: insufficient. Source: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.
  11. Evidence row 616

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 37652708

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes.
  12. Evidence row 617

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39357769

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells.
  13. Evidence row 618

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 41645347

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents.
  14. Evidence row 619

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.